<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040833</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Progressive multifocal leucoencephalopathy in aids patients. Hepatotoxicity of hart in patients with hepatitis B or C</dc:title>
<dc:description xml:lang="en">Progressive multifocal leukoencephalopathy (PML) develops in 1-8% of patients with AIDS, for which it is a disease-defining condition. PML presents mainly in severely immunocompromised male intravenous drug users, having viral loads greater than log5 RNA copies/mL and CD4 populations lower than 150 cells/mm3. Death of AIDS patients with PML occurred after only 4 to 6 months before the introduction of highly active antiretroviral therapies (HAART), the only ones that have shown to prolong survival. Viral hepatitis is not the only liver condition affecting patients with AIDS, opportunistic infections and neoplasms, such as lymphoma and Kaposi&#146;s sarcoma, as well as biliary disease are also encountered but, fortunately, they are currently less frequent as a result of the new antiretroviral treatments. The risks of HAART hepatotoxicity in patients with hepatitis B or C have been studied by several groups</dc:description>
<dc:creator>Zancada Díaz de Entre-Sotos, F</dc:creator>
<dc:creator>Calderón Mariño, N</dc:creator>
<dc:creator>Blanco Barrios, A</dc:creator>
<dc:creator>Gutiérrez Vivas, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La leucoencefalopatía multifocal progresiva (LMP) es un criterio diagnóstico de sida. Afecta al 1-8% de los pacientes con sida (según las series), con supervivencias de 4-6 meses antes de las terapias antirretrovirales de gran actividad (TARGA). Se observa sobre todo en pacientes usuarios a drogas por vía parenteral, con inmunodeficiencia avanzada (Carga vírica: log 5 copias/ ml y CD4 &lt; 150/ mm3). Parece que sólo los pacientes bajo tratamiento con TARGA consiguen supervivencias más prolongadas. Las hepatitis víricas no son el único problema que se ha visto en pacientes con infección por VIH. Infecciones oportunistas y neoplasias, tales como el linfoma y sarcoma de Kaposi y problemas biliares han sido observados, si bien estos no son muy frecuentes, gracias a los nuevos tratamientos antirretrovirales. Sin embargo en pacientes con Hepatitis B o C el tratamiento antirretroviral puede causar mayor hepatotoxicidad</dc:description>
<dc:source>An Med Interna;22(8): 376-378, ago. 2005.</dc:source>
<dc:identifier>ibc-040833</dc:identifier>
<dc:title xml:lang="es">Leucoencefalopatía multifocal progresiva en pacientes con sida. Hepatotoxicidad de la terapia de alta eficacia (TARGA) en pacientes con coinfección por VHB o VHC</dc:title>
<dc:subject>^d23504^s22073</dc:subject>
<dc:subject>^d27868^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d23255^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d6664^s22012</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d29364^s22012</dc:subject>
<dc:subject>^d38332^s22068</dc:subject>
<dc:subject>^d6664^s22016</dc:subject>
<dc:subject>^d29364^s22016</dc:subject>
<dc:subject>^d29431^s22045</dc:subject>
<dc:subject>^d38332^s22020</dc:subject>
<dc:subject>^d38332^s22073</dc:subject>
<dc:subject>^d29437^s22012</dc:subject>
<dc:subject>^d29437^s22067</dc:subject>
<dc:subject>^d27868^s22012</dc:subject>
<dc:subject>^d30351^s22012</dc:subject>
<dc:subject>^d30933^s22073</dc:subject>
<dc:subject>^d29437^s22016</dc:subject>
<dc:subject>^d30351^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200508</dc:date>
</metadata>
</record>
</ibecs-document>
